Treatment of Functional Dyspepsia with Amitriptyline

Guideline-Based Treatment Algorithm

The British Society of Gastroenterology recommends starting with proton pump inhibitors (PPIs) at standard doses for 4-8 weeks as first-line therapy for functional dyspepsia 1
If H. pylori positive, the British Society of Gastroenterology guidelines suggest providing eradication therapy first 1
The British Society of Gastroenterology guidelines recommend amitriptyline as second-line therapy for functional dyspepsia, starting at 10 mg once daily and titrating to 30-50 mg daily, with moderate-quality evidence and strong guideline support 1

The British Society of Gastroenterology guidelines suggest explaining to patients that amitriptyline is being used as a "gut-brain neuromodulator" rather than for depression, to improve adherence 1
Patients should be counseled about common side effects of amitriptyline, including dry mouth (25%), somnolence (54%), constipation (13%), and weight gain (12%), as recommended by the British Society of Gastroenterology guidelines 1

The British Society of Gastroenterology guidelines recommend using amitriptyline first at neuromodulator doses (10-50 mg) for patients with depression or anxiety comorbidity, as it treats both functional dyspepsia and mood symptoms 1
For patients with cardiac conditions, the British Society of Gastroenterology guidelines suggest that amitriptyline requires caution due to anticholinergic effects and potential QT prolongation 1

The British Society of Gastroenterology guidelines recommend not skipping first-line therapy and using amitriptyline only after adequate trials of PPIs or H. pylori eradication 1
The British Society of Gastroenterology guidelines suggest not starting amitriptyline at high doses, but rather beginning at 10 mg to minimize side effects and improve tolerability 1
The British Society of Gastroenterology and other guidelines do not recommend using mirtazapine as first-line neuromodulator due to lack of guideline support and concerning safety profile 1, 2

The British Society of Gastroenterology recommends H. pylori eradication as first-line therapy for patients with functional dyspepsia who test positive, with a strong recommendation and high-quality evidence 3
Proton pump inhibitors (PPIs) are recommended as first-line therapy with a strong recommendation and high-quality evidence, according to the British Society of Gastroenterology 4, 5, 3
Histamine-2 receptor antagonists are recommended as first-line therapy with a weak recommendation and low-quality evidence, according to the British Society of Gastroenterology 5, 3

Tricyclic antidepressants (TCAs) are the preferred second-line therapy for functional dyspepsia, with amitriptyline 10 mg once daily as the initial dose, titrating to 30-50 mg daily, as recommended by the British Society of Gastroenterology with a strong recommendation and moderate-quality evidence 6, 3, 7
If neither acotiamide nor domperidone is available or appropriate, the British Society of Gastroenterology recommends moving directly to TCAs as second-line therapy rather than pursuing other prokinetics with even less evidence 6, 3, 7

The British Society of Gastroenterology provides a weak recommendation with low-quality evidence for the use of prokinetics, including acotiamide, in the treatment of functional dyspepsia 4, 5, 3
Domperidone is not recommended due to cardiac safety concerns, including QT prolongation and potential for serious arrhythmias, as noted by the British Society of Gastroenterology 3

Acotiamide has a superior safety profile compared to domperidone, with no cardiac safety concerns reported, as noted by the British Society of Gastroenterology 4, 5, 3
The availability of acotiamide and domperidone is limited in many countries, which is a major consideration in the treatment of functional dyspepsia, as noted by the British Society of Gastroenterology 4, 5, 3